IP Library Granted Patent US 9,314,489
Granted Patent B2
US 9,314,489 · App. 14/349,907 · Granted Apr 19, 2016

Bacterium for use as a probiotic for nutritional and medical applications

Inventors: Denise Kelly (Aberdeen, GB); Imke Mulder (Aberdeen, GB)
Assignee: 4D Pharma Research Limited
A61K35/741A23K1/009A23L1/3014A61K35/74C12N1/20A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,314,489
App. No.
14/349,907
Granted
Apr 19, 2016
Kind
B2
Abstract

A first aspect of the invention relates to the bacterial species Roseburia hominis for use in: regulating the immune system of a subject treating an immune disorder; treating an intestinal disorder; improving intestinal microbiota; regulating the innate immune system of a subject; regulating the adaptive immune system of a subject; regulating appetite in a subject; promoting Tregs and immune tolerance; promoting gut health in a subject; and/or maintaining immune homeostasis in a subject. Further aspects of the invention relate to compositions comprising Roseburia hominis.

Claims (10)

1. A method of treating a disorder selected from an immune disorder, an inflammatory disorder and an intestinal disorder in a subject, said method comprising administering to the subject a pharmaceutically effective amount of the bacterial species Roseburia hominis.

2. The method of claim 1 , wherein the disorder is selected from irritable bowel syndrome (IBS), colitis, inflammatory bowel disorder (IBD), pouchitis, functional dyspepsia, functional constipation, functional diarrhoea, functional abdominal pain, functional bloating, Epigastric Pain Syndrome, Postprandial Distress Syndrome, gastrointestinal reflux disease (GERD), autoimmune diseases, allergies, coeliac disease, atopic diseases, rhinitis, necrotising enterocolitis, and combinations thereof.

3. The method of claim 1 , said method comprising administering to the subject a pharmaceutical composition comprising the bacterial species Roseburia hominis and a pharmaceutically acceptable excipient, carrier or diluent.

4. The method of claim 1 , said method comprising administering to the subject a nutritional supplement comprising the bacterial species Roseburia hominis and a nutritionally acceptable excipient, carrier or diluent.

5. The method of claim 1 , said method comprising administering to the subject a probiotic composition comprising the bacterial species Roseburia hominis.

6. The method of claim 1 , said method comprising administering to the subject a feedstuff, food product, dietary supplement, nutritional supplement or food additive comprising the bacterial species Roseburia hominis.

7. The method of claim 1 , wherein the inflammatory bowel disorder is selected from Crohn's disease and ulcerative colitis.

8. The method of claim 2 , wherein the functional diarrhoea is selected from the group consisting of antibiotic associated diarrhoea, traveller's diarrhoea and pediatric diarrhoea.

9. The method of claim 2 , wherein the autoimmune disease is selected from the group consisting of diabetes, arthritis, multiple sclerosis and psoriasis.

10. The method of claim 2 , wherein the atopic disease is atopic dermatitis.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2023
From: 4D PHARMA PLC; 4D PHARMA RESEARCH LIMITED
To: CJ BIOSCIENCE, INC.
Reel/Frame 063992/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: OXFORD FINANCE LUXEMBOURG S.A R.L.
To: ARMISTICE CAPITAL MASTER FUND LTD.
Reel/Frame 061806/0371 →
INTELECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 30, 2021
From: 4D PHARMA PLC; 4D PHARMA RESEARCH LIMITED; 4D PHARMA CORK LIMITED; 4D PHARMA DELAWARE INC.
To: OXFORD FINANCE LUXEMBOURG S.A R.L.
Reel/Frame 057042/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2016
From: KELLY, DENISE
To: GT BIOLOGICS LIMITED
Reel/Frame 037918/0762 →
CHANGE OF NAME Recorded Feb 22, 2016
From: GT BIOLOGICS LIMITED
To: 4D PHARMA RESEARCH LIMITED
Reel/Frame 037789/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2016
From: MULDER, IMKE
To: 4D PHARMA RESEARCH LIMITED
Reel/Frame 037879/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2016
From: MULDER, IMKE
To: 4D PHARMA RESEARCH LIMITED
Reel/Frame 037879/0939 →
Priority Claims (1)
GB 1117313.5 · Oct 7, 2011 · national
Continuity (1)
Related Publication 20150132264A1 · May 14, 2015